Chlamydia screening criteria must go beyond sex partners, OC use.
D000290:Adnexa Uteri; D000554:Ambulatory Care Facilities; D000569:Americas; D001695:Biology; D002140:California; D002689:Chlamydia; D003362:Cost-Benefit Analysis; D019049:Developed Countries; D003906:Developing Countries; D003933:Diagnosis; D004194:Disease; D005069:Evaluation Studies as Topic; D005835:Genitalia; D005836:Genitalia, Female; D006285:Health Planning; D007239:Infections; D009656:North America; D009934:Organization and Administration; D000292:Pelvic Inflammatory Disease; D010827:Physiology; D011154:Population Characteristics; D012106:Research; D012749:Sexually Transmitted Diseases; D014481:United States; D014566:Urogenital System
Adnexal Effects; Adnexitis--prevention and control; Americas; Bacterial And Fungal Diseases; Biology; California; Chlamydia--prevention and control; Clinic Activities; Cost Benefit Analysis; Cost Effectiveness; Developed Countries; Developing Countries; Diseases; Evaluation; Evaluation Indexes; Evaluation Methodology; Examinations And Diagnoses--cost; Genital Effects, Female; Genitalia; Genitalia, Female; Infections; North America; Northern America; Organization And Administration; Pelvic Inflammatory Disease; Physiology; Population At Risk; Program Activities; Programs; Quantitative Evaluation; Reproductive Tract Infections; Research Methodology; Sexually Transmitted Diseases; United States; Urogenital Effects; Urogenital System